Heme biosynthetic pathway and blood–brain barrier permeability state

The "Heme biosynthetic pathway and blood-brain barrier permeability state" refers to the metabolic sequence of heme production in relation to the integrity of the physiological barrier separating the circulation from the brain parenchyma. The heme biosynthetic pathway involves eight enzymes that convert glycine and succinyl-CoA into heme, with Protoporphyrin IX (PpIX) serving as the penultimate intermediate (Ponka, 1997, Blood). In clinical neuro-oncology, this system is exploited using 5-aminolevulinic acid (5-ALA), a precursor that bypasses the pathway's rate-limiting step. Malignant glioma cells often exhibit increased 5-ALA uptake due to a compromised blood-brain barrier and altered enzyme activities, such as decreased ferrochelatase, which results in the selective accumulation of fluorescent PpIX (Stummer et al., 2006, Lancet Oncology). This phenomenon allows for fluorescence-guided surgery, enabling real-time visualization of tumor margins that are otherwise indistinguishable from healthy tissue. Additionally, the state of the blood-brain barrier determines the delivery efficiency of these metabolic precursors and the potential for neurotoxicity from pathway intermediates. Understanding this interplay is crucial for optimizing photodynamic therapies and diagnosing metabolic disorders like porphyria that affect the central nervous system (StatPearls, 2023).

Other names

Heme biosynthesisBlood-brain barrier permeability5-ALA-PpIX pathwayPorphyrin metabolism in the CNS

The administration of exogenous 5-aminolevulinic acid (5-ALA) bypasses the rate-limiting enzyme ALA synthase in the heme biosynthetic pathway. In tissues with increased blood-brain barrier (BBB) permeability and altered enzymatic profiles (such as reduced ferrochelatase), this leads to the selective accumulation of the fluorescent intermediate Protoporphyrin IX (PpIX), which is used for tumor visualization and photodynamic therapy (Stummer et al., 2006, Lancet Oncology; Hefti et al., 2008, Journal of Neuro-Oncology).